The emerging role of IMD 0354 on bone homeostasis by suppressing osteoclastogenesis and bone resorption, but without affecting bone formation

[1]  E. Tsiridis,et al.  Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss , 2019, Expert opinion on pharmacotherapy.

[2]  Ziqing Li,et al.  Regulator of G Protein Signaling Protein 12 (Rgs12) Controls Mouse Osteoblast Differentiation via Calcium Channel/Oscillation and Gαi‐ERK Signaling , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  R. Sirdeshmukh,et al.  LYN, a key mediator in estrogen-dependent suppression of osteoclast differentiation, survival, and function. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[4]  A. Qin,et al.  Psoralen accelerates bone fracture healing by activating both osteoclasts and osteoblasts , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  A. Qin,et al.  SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[6]  Xiong Guo,et al.  Cryptotanshinone inhibits RANKL‐induced osteoclastogenesis by regulating ERK and NF‐κB signaling pathways , 2018, Journal of cellular biochemistry.

[7]  S. Bicciato,et al.  Induction of immunosuppressive functions and NF-κB by FLIP in monocytes , 2018, Nature Communications.

[8]  Jiandie D. Lin,et al.  PGC-1α Controls Skeletal Stem Cell Fate and Bone-Fat Balance in Osteoporosis and Skeletal Aging by Inducing TAZ. , 2018, Cell stem cell.

[9]  J. Tombran-Tink,et al.  Pigment epithelium derived factor regulates human Sost/Sclerostin and other osteocyte gene expression via the receptor and induction of Erk/GSK-3beta/beta-catenin signaling. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[10]  Y. Soh,et al.  Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice. , 2018, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[11]  Y. Tabata,et al.  Coupling of bone resorption and formation by RANKL reverse signalling , 2018, Nature.

[12]  N. Ratcliffe,et al.  The NF-κB Inhibitor, IMD-0354, Affects Immune Gene Expression, Bacterial Microbiota and Trypanosoma cruzi Infection in Rhodnius prolixus Midgut , 2018, Front. Physiol..

[13]  Jiandie D. Lin,et al.  PGC-1α Controls Skeletal Stem Cell Fate and Bone-Fat Balance in Osteoporosis and Skeletal Aging by Inducing TAZ. , 2018, Cell stem cell.

[14]  B. Fabry,et al.  NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  Gabrielle E Foxa,et al.  LRP1 Suppresses Bone Resorption in Mice by Inhibiting the RANKL‐Stimulated NF‐κB and p38 Pathways During Osteoclastogenesis , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  Kyung-Hyun Park-Min.  Mechanisms involved in normal and pathological osteoclastogenesis , 2018, Cellular and Molecular Life Sciences.

[17]  C. Quiroga,et al.  A new role for HERPUD1 and ERAD activation in osteoblast differentiation and mineralization , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  R. Kayal,et al.  OC‐STAMP promotes osteoclast fusion for pathogenic bone resorption in periodontitis via up‐regulation of permissive fusogen CD9 , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  K. Cengel,et al.  Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation‐induced osteoporosis , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Jian-qiao Hong,et al.  Low-intensity pulsed ultrasound inhibits RANKL-induced osteoclast formation via modulating ERK-c-Fos-NFATc1 signaling cascades. , 2018, American journal of translational research.

[21]  Huilin Yang,et al.  Inhibitory effects of melatonin on titanium particle-induced inflammatory bone resorption and osteoclastogenesis via suppression of NF-κB signaling. , 2017, Acta biomaterialia.

[22]  Qianchuan Zhao,et al.  Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Eugenia G. Giannopoulou,et al.  Hypoxia‐Sensitive COMMD1 Integrates Signaling and Cellular Metabolism in Human Macrophages and Suppresses Osteoclastogenesis , 2017, Immunity.

[24]  Eugenia G. Giannopoulou,et al.  MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERR&agr; , 2017, The Journal of clinical investigation.

[25]  A. Zannettino,et al.  EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  G. Mccarthy,et al.  Intra-articular basic calcium phosphate and monosodium urate crystals inhibit anti-osteoclastogenic cytokine signalling. , 2016, Osteoarthritis and cartilage.

[27]  A. Qin,et al.  Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo , 2015, Scientific Reports.

[28]  I. Kwon,et al.  PIN1 Inhibition Suppresses Osteoclast Differentiation and Inflammatory Responses , 2015, Journal of dental research.

[29]  A. Itai,et al.  IκB kinase-β inhibitor IMD-0354 beneficially suppresses retinal vascular permeability in streptozotocin-induced diabetic mice. , 2014, Investigative ophthalmology & visual science.

[30]  D. Graves,et al.  Non-canonical Wnt4 prevents skeletal aging and inflammation by inhibiting NF-κB , 2014, Nature Medicine.

[31]  S. Goodman,et al.  Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a therapeutic target. , 2014, Acta biomaterialia.

[32]  I. Komuro,et al.  Inhibition of NF-κB activation by a novel IKK inhibitor reduces the severity of experimental autoimmune myocarditis via suppression of T-cell activation. , 2013, American journal of physiology. Heart and circulatory physiology.

[33]  R. Reisfeld,et al.  IMD-0354 Targets Breast Cancer Stem Cells: A Novel Approach for an Adjuvant to Chemotherapy to Prevent Multidrug Resistance in a Murine Model , 2013, PloS one.

[34]  A. Itai,et al.  Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354. , 2013, Cardiovascular research.

[35]  R. Baron,et al.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. , 2013, The Journal of clinical investigation.

[36]  J. Kanis,et al.  Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  Georg Schett,et al.  Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment , 2012, Nature Reviews Rheumatology.

[38]  Y. Kadono,et al.  Regulation of RANKL‐induced osteoclastogenesis by TGF‐β through molecular interaction between Smad3 and Traf6 , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  Hui Li,et al.  Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy‐induced bone loss by regulating RANKL‐mediated NF‐κB and MAPK signaling pathways , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  Ralph Müller,et al.  Guidelines for assessment of bone microstructure in rodents using micro–computed tomography , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  K. Guan,et al.  Inhibition of osteoblastic bone formation by nuclear factor-κB , 2009, Nature Medicine.

[42]  M. Mack,et al.  Estrogen-dependent and C-C chemokine receptor-2–dependent pathways determine osteoclast behavior in osteoporosis , 2009, Nature Medicine.

[43]  A. Raucci,et al.  Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways , 2008, Journal of cellular physiology.

[44]  S. Migliaccio,et al.  The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis , 2007, Clinical interventions in aging.

[45]  L. Raisz.  Pathogenesis of osteoporosis: concepts, conflicts, and prospects. , 2005, The Journal of clinical investigation.

[46]  T. Nakaki,et al.  NF-κB as a Therapeutic Target for Cardiovascular Disease , 2002, Heart Drug.

[47]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[48]  P. Chambon,et al.  Aberrant Growth Plate Development in VDR/RXRγ Double Null Mutant Mice. , 2001, Endocrinology.

[49]  P. Chambon,et al.  Aberrant growth plate development in VDR/RXR gamma double null mutant mice. , 2001, Endocrinology.